KGX105
/ KangaBio
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
July 15, 2026
Phase I Study of Single-Agent KGX105 in Patients With Advanced or Metastatic Solid Tumors
(clinicaltrials.gov)
- P1 | N=85 | Not yet recruiting | Sponsor: Kangabio AUSTRALIA LTD PTY
First-in-human • New P1 trial • Oncology • Solid Tumor
March 26, 2025
KGX105, a conditionally active prodrug of EGFRxCD3 T cell engager induces anti-tumor potency
(AACR 2025)
- "The pilot toxic study to evaluate the safety and toxicokinetics of KGX105 is ongoing in Cynomolgus monkeys. The studies presented herein support KGX105 as a promising novel therapeutic to target a wide range of EGFR-expressing cancers with the potential to avoid the life-threatening on-target toxicities and systemic cytokine release."
Colorectal Cancer • Hematological Malignancies • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1